Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Riha Vaidya Joseph M Unger Lu QianKatherine MinichielloRoy S Herbst David R Gandara Joel W Neal Ticiana A Leal Jyoti D PatelKonstantin H DragnevSaiama N WaqarMartin J EdelmanEllen V SigalStacey J AdamShakun MalikCharles D BlankeMichael L LeBlancKaren KellyJhanelle E GrayMary W Redman

Published in: JCO precision oncology (2023)

Master protocols may improve access to trials using novel therapeutics for older patients and socioeconomically vulnerable patients compared with conventional trials, but specific patient exclusion criteria influenced demographic composition. Further research examining participation barriers for under represented racial or ethnic minorities in precision medicine clinical trials is warranted.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
prognostic factors
patient reported outcomes
study protocol
high density